Cook Medical's Ongoing Zilver PTX Trial Data Show Higher Freedom From Target Lesion Revascularization (TLR) Rates Compared to Angioplasty and Bare Metal Stenting After Three Years
New data were presented at the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) meeting
BLOOMINGTON, Ind.--(BUSINESS WIRE)--Aug 13, 2012 - Previously unreleased three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease indicate that Cook Medical's paclitaxel-eluting peripheral vascular stent demonstrated 83.0 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479 patient study.
Gary M. Ansel, M.D., Zilver PTX study principal investigator, presented the study findings at the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) meeting last month in Niigata, Japan.
The device is currently available for sale in Japan after approval from the Pharmaceuticals and Medical Devices Agency on January 24 and is now available in more than 45 countries. It is currently under U.S. Food and Drug Administration review and is not available for sale in the United States. Dr. Ansel is a paid consultant to Cook Medical with respect to its medical devices.
About Cook Medical
A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter and LinkedIn.
Posted: August 2012